ArsenalBio Secures $325M with Regeneron, BMS Backing
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
- Latest
- Trending
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
Discover investment opportunities in smaller AI stocks often overlooked by investors focused on giants like Nvidia.
Notre Dame uses microgravity to enhance early cancer detection via blood tests, potentially transforming diagnostic methods.
Ethereum's Distributed Validator Tech offers a decentralized, resilient solution for financial systems, reducing centralization risks.
Intel CEO Pat Gelsinger to present cost-cutting strategy and propose selling Altera division to board for approval.
Exploring the reasons why Canada's big banks are slow to invest in renewable energy sectors.
Exploring Permira's strategies in tech investments, M&A, and IPOs amidst evolving market conditions.
Dogecoin faces challenges despite a 6% rise, as metrics show potential hurdles.
Tech stocks slide, Dow Jones lower as investors await Fed comments on interest rate changes at Jackson Hole.
Ethereum shows signs of breaking $2.8K barrier with strong on-chain signals and growing investor confidence.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.